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Background: The Rare and Undiagnosed Diseases Diagnostic Service (RUDDS) refers to a genomic diagnostic
platform operating within the Western Australian Government clinical services delivered through Genetic Services
of Western Australia (GSWA). GSWA has provided a state-wide service for clinical genetic care for 28 years and it
serves a population of 2.5 million people across a geographical area of 2.5milion Km2. Within this context, GSWA
has established a clinically integrated genomic diagnostic platform in partnership with other public health system
managers and service providers, including but not limited to the Office of Population Health Genomics, Diagnostic
Genomics (PathWest Laboratories) and with executive level support from the Department of Health. Herein we
describe report presents the components of this service that are most relevant to the heterogeneity of paediatric
clinical genetic care.
Results: Briefly the platform : i) offers multiple options including non-genetic testing; monogenic and genomic
(targeted in silico filtered and whole exome) analysis; and matchmaking; ii) is delivered in a patient-centric manner
that is resonant with the patient journey, it has multiple points for entry, exit and re-entry to allow people access to
information they can use, when they want to receive it; iii) is synchronous with precision phenotyping methods; iv)
captures new knowledge, including multiple expert review; v) is integrated with current translational genomic
research activities and best practice; and vi) is designed for flexibility for interactive generation of, and integration
with, clinical research for diagnostics, community engagement, policy and models of care.
Conclusion: The RUDDS has been established as part of routine clinical genetic services and is thus sustainable,
equitably managed and seeks to translate new knowledge into efficient diagnostics and improved health for the
whole community.
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Table 1 The power of a diagnosis
Benefits Comments
Certainty The power of knowing the cause
of the condition at the end of the
diagnostic odyssey, including
improved prognostication.
Reduced Isolation Offering the possibility of
connection for shared experience.
Reduce unnecessary investigations No further need for investigations
which may be invasive,
time-consuming and/or costly.
Access to improved or best practice
medical care, including reducing
inappropriate management
Targeted follow-up and
surveillance by what is known
from the diagnosed condition
and biologically related disorders.
Possibility of drug repurposinga.




A molecularly confirmed genetic
diagnosis provides options for
prenatal or pre-implantation
genetic diagnosis.
Access to social and educational
services
Available for selected other rare
disorders.
adrug repurposing: using a given drug for a new indication (disease)
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Rare diseases are a health priority that collectively are
estimated to affect up to 6–8 % of the population [1–4].
Many rare diseases have their onset in childhood, con-
tinue lifelong, are complex with multisystem dysfunction
and are disabling and burdensome to individuals, fam-
ilies and the healthcare system. There are 5,000–8,000
known rare diseases, and because of their individual
rarity achieving a diagnosis is particularly challenging. In
a European study, 25 % of individuals waited 5–30 years
for a diagnosis and in 40 % of instances the initial diag-
nosis was wrong [5]. A recent survey showed similar
findings in Australia including that approximately 30 %
of patients waited for more than 5 years to receive a
diagnosis, a similar number saw more than 6 doctors
before receiving a diagnosis and half had at least one
incorrect diagnosis [6] . Reflecting the priority for the
global rare diseases community, local and international
efforts have been developed to address this diagnostic
odyssey as an accurate diagnosis is the bedrock of best
practice medical care. Stated differently, the “Diagno-
sis—the Value of Knowing— is the foundation of quality
healthcare. Its value is undeniable—to patients, to
doctors, and to the underlying financial health of our
healthcare system”. Furthermore, “accurate diagnosi-
s—and the appropriate use of diagnostic tools—is a key
driver toward the successful transformation of our
healthcare system” [7].
Given that most rare diseases are genetic in origin, the
diagnostic process historically often included a consult-
ation with a clinical genetic service which consisted of a
clinical assessment followed by investigations which may
include sequential monogenic testing where deemed
clinically appropriate. The advent of chromosomal
microarray, followed by the clinical application of mas-
sively parallel sequencing, either targeted (in the sense
of a multi-gene panel) or genome wide (whole exome or
whole genome), has resulted in a markedly increased
diagnostic yield in rare diseases [8] and this is modifying
the diagnostic paradigm. International experience with
the clinical implementation of genomic sequencing
across the diversity of presentations typical of clinical
genetic practice, showed a diagnostic yield around 25-
30 %. Yang et al. reported an observational study of
whole-exome sequencing which provided a molecular
diagnosis for 25 % of a cohort of predominantly paediat-
ric patients with suspected genetic disorders. The sub
cohort with the greatest detection rate was for neuro-
logical plus other organ system involvement [9]. Retterer
et al. described a diagnostic yield of 28.8 % for a hetero-
geneous group of presentations. The highest yield was
for patients who had disorders involving hearing, vision,
the skeletal muscle system, the skeletal system and
multiple congenital anomalies [10]. Lee et al. reportedthe outcomes of consecutive patients with undiagnosed
suspected genetic conditions seen at a single clinical
genetic centre. Most cases were submitted from geneti-
cists and had substantial prior genetic investigation.
They often presented with clinical symptoms that either
involved more than one body system or were deemed to
be highly genetically heterogeneous. Approximately
two thirds were children. The overall molecular diag-
nosis rate was 26 % [8]. Atwal et al. reviewed their
institutions clinical experience and surveyed multiple
other centres, from this heterogeneous group of
centres and testing platforms, cumulatively there was
22.8 % success rate [11].
Higher success rates have occurred in the setting of
research projects with highly selected cohorts, as distinct
from the heterogeneity of presentations as seen in a
clinical practice setting.
It is important to balance the diagnostic yield and the
multiple attendant benefits of a confirmed molecular
diagnosis (see Table 1) against the direct (test, analysis)
and potential indirect costs of testing (such as with
follow up of variants of uncertain significance). These
considerations are especially important in the setting
of limited health budgets and with consideration of
primum non nocere. Formal health economic and econo-
metric studies are underway to provide important
evidence for helping to explore and evaluate financial
questions. Whilst these are awaited, the burden on
patients, their families and clinical service providers of the
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eases demands a pragmatic and timely approach that can
immediately deliver against this need, whilst providing
clinical data to assist ongoing economic studies that are
tailored to the local health context. Equally, it is crucial
that service delivery is provided equitably. We describe
the initial outcomes of the RUDDS, a diagnostic pipeline
in a public health system operating from within a state-
wide clinical genetic service to address the diagnostic
odyssey of individuals living with rare diseases.
Methods
Individuals seen in outpatient clinics at GSWA received a
genetic consultation and clinical assessment (phenotyping)
by the attending physician. This includes: ascertainment
of history; physical examination, including 2-dimensional
and 3-dimensional photographs, anthropometric meas-
urements; and documentation of relevant investigation
results. Relevant complex undiagnosed cases, included,
but were not limited to, when in silico filtered or whole
exome/ genome analysis was being considered. Cases were
presented at a weekly multi-clinician meeting to achieve a
consensus for further investigations such as (i) non-gene-
based testing (e.g. imaging and biochemistry), to either
confirm a diagnosis or to refine the phenotype prior to, or
in partnership with, genetic testing; (ii) recommendation
of additional expert review; (iii) monogenic testing; and
(iv) targeted in silico filtered exome or whole exome ana-
lysis. A clinical consensus decision directed investigation
course e.g. request for further phenotyping, including
deferring of further testing with review with the passage of
time, or the variety of testing options, including genomic
ones. Of those that preceded to genomic testing, the ma-
jority (74/77) analyses were performed as in silico filtered
panels, with familial follow-up of variants as required. The
approach to whole exome sequencing (e.g. sib-pair, trio or
most distantly related family members with the same
unique phenotype) was a case-by-case decision made with
discussion between clinical and laboratory staff. For those
where massively parallel sequencing failed to identify a
pathogenic mutation, a matchmaking service for undiag-
nosed patients was offered. Specifically, in the first
instance, by offer of submission to Phenome Central. Add-
itionally, patients were offered recruitment into research
projects aimed at identifying a diagnosis through the
development of novel genomic analyses, principally
SeqNextGen which is a translational research program
contributing to improving the diagnosis of rare genetic
diseases and models of care for genomic diagnostics for
rare diseases and developmental anomalies. SeqNextGen
was implemented as a recipient of a pipeline from the
RUDDS with aims including to improve data analytics for
rare diseases diagnosis, and relatedly to be adaptable to
the heterogeneity and temporal evolution of in-serviceclinical genomic testing. Those without (and with) a con-
firmed genomic diagnosis are given the option to share
genomic data with this study. Those with a confirmed
genomic diagnosis serve as positive controls for validation
of new data analytic approaches. The data from those
without a diagnosis can be re-analysed with new ap-
proaches in case this yields a definitive answer. Any poten-
tial diagnosis is then discussed with managing clinician
before any clinical laboratory confirmation is performed
prior to contacting the patient. This project also incorpo-
rates patient and family experience surveys. A schematic
of the RUDDS is in Fig. 1.
The design of in silico filtered panels was performed
as a partnership between the laboratory staff and
clinicians and pragmatic decisions balancing cost,
throughput, detection rate, available monogenic testing,
laboratory and clinical experience of the phenotype
under investigation, and the likely rate of determining
variants of uncertain significance were made. Largely,
gene panels were created to cover groups of presenta-
tions that are frequently represented in clinical genetics
clinics, including multisystem diseases, with and without
intellectual disability, that are typically associated with
locus heterogeneity and often involve common bio-
logical pathways. Panels were iterated from a foundation
of more than 200 in-house monogenic tests. They
included tests for cohesinopathies and phenotypically/
biologically related disorders (e.g. Cornelia de Lange
Syndrome and BAF complex disorders (e.g. Coffin-Siris
syndrome)) disorders associated with absent or severe
speech impediment (e.g. Angelman syndrome and
overlapping disorders); RASopathies (e.g. Noonan syn-
drome); overgrowth disorders (e.g. Sotos syndrome);
ciliopathies (e.g. primary ciliary dyskinesias and auto-
somal recessive polycystic kidney disorders); and pre-
sumptive X-linked mental retardation. Less frequently,
other selected disorders were investigated based on clin-
ical need coupled with locus heterogeneity and/or on
prohibitive costs of send-away tests. Creation of in silico
targeted panels that was performed for such purposes
included those for Kabuki syndrome, epidermolysis
bullosa, cutis laxa-associated conditions, corneal dystro-
phies and hereditary haemorrhagic telangiectasia.
Reflecting the practicality of testing within a clinical
setting and the rapidly evolving technological landscape,
massively parallel sequencing was performed on multiple
platforms. Briefly, libraries were prepared using the Ion
Ampliseq Exome Kit (Life Technologies) or with the
NEBNext Ultra DNA Library Kit (New England BioLabs)
and captured with the TargetSeq Exome Kit (Thermo-
Fisher Scientific). Sequencing was performed on the Ion
Proton Sequencer (Life Technologies) or the SOLiD
5500XL (Applied Biosystems) instruments, respectively.
A minimum of 85 % of gene regions included in the data
Fig. 1 Program schematic. This schematic represents the Rare and Undiagnosed Diseases Diagnostic Service (RUDDS)
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typically the proportion was much higher (>90 fold) for
most samples. Alignment and variant calling were per-
formed using Torrent Suite software (Life Technologies)
or LifeScope software (Applied Biosystems). Variants
were annotated, filtered and analysed in Bench Lab NGS
(Cartagenia).
Known or likely pathogenic variants were confirmed
by Sanger sequencing in a National Association of Testing
Laboratories, Australia (NATA)-accredited laboratory
(Diagnostic Genomics, PathWest).
Close liaison between clinicians, genetic pathologists
and other diagnostic genomic scientists was frequent
and facilitated by regular meetings. Genetic counsellors
provided critical expertise to all parts of the diagnostic
platform including patient consent, coordination and
ongoing patient and family support. The clinical service
and associated translational research was run in
partnership with the key input of patient advocacy
groups, including Rare Voices Australia (www.rarevoi-
ces.org.au australia.org.au).
Importantly, equitable health care delivery was sup-
ported by delivering the RUDDS within a clinical state-
wide public health service that is a focused on improving
genetic health care for the community in the metropol-
itan area and, through outreach pathways, to rural and
remote regions providing, including Aboriginal and non-
Aboriginal Australians.Herein, we focus primarily on children with the het-
erogeneous presentations typical of paediatric clinical
genetics who were assessed through the diagnostic plat-
form and progressed to in-house genomic investigations
(in silico targeted panels, whole exome sequencing) from
July 2013 – July 2015. We have excluded neuromuscular
diseases which are largely managed through neurological
services; cardiac diseases (structural, electrical and
aortopathies) and familial cancers which in the main
have been provided for adults through familial cancer or
cardiogenetic pathways; and all genomic investigations
performed out of state or country. We also excluded
those diagnosed by epigenetic, radiological or other
means.Results and discussion
The overarching achievement is the creation of an im-
perfect but agile and iteratively improving, diagnostic
platform within the public health service, that is aligned
to unmet need, and that supports equitable state-wide
diagnostic health care provision through the integration
of genomic diagnostics. Notably, this improved in-house
causative monogenic detection rate from a historical
service baseline of 10 – 30 % for this heterogeneous and
diagnostically challenging clinical cohort. The RUDDS
is consistent with fundamental tenants of clinical gen-
etic service delivery, including excellent phenotyping,
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staff and alignment to the patient journey. Primary
outcomes of the RUDDS included:
Firstly, that it was delivered in a patient-centric man-
ner resonant with the patient journey, specifically that as
it is not limited to the duration of a research project,
nor to a static consent process, that patients can engage
with or leave the platform at various stages and at times
relevant to them, providing news they can use and when
they are ready to receive it. Additionally, through
provision in a state-wide service, including outreach
clinics, it could be provided with geographic equity. Sec-
ondly, by integration in clinical service , multiple options
including monogenic and genomic (targeted and whole
exome) analysis, non-gene based testing, and matchmak-
ing could be offered. Thirdly, it was synchronous with
precision phenotyping methods, including that 3-D facial
analysis could be provided. Even if it was “just” the
provision of a 3-D image that could be interrogated at
clinical case review to provide an increased depth of in-
formation compared to 2D images. Fourthly, it captured
new knowledge, including multiple expert reviews, spe-
cifically the documentation and process of team discus-
sions around each individual either before and/ or after
testing provided opportunities for collective up-skilling
with likely future benefit to future families. For instance,
multiple cases with clinical indicators of possible mosai-
cism and normal testing on peripheral blood, altered
clinical practice for tissue selection in subsequent cases,
and lead to new processes for acquiring the relevant
samples. Additionally, the new knowledge of the mTOR
mutation offered a new alternative for seizure treatment.
Fifthly, integration with current translational genomic
research activities, specifically, but not limited to the the
SeqNextGen project described above. In some instances,
patients that could not be resolved with the SeqNextGen
project were recruited into research projects with
laboratories with specific phenotype domain expertise.
Also, as a by-product of the relationships established
through this collaboration, and following the case of a
familial mTOR described above, the first genomic
reference range data for Aboriginal Australians [12] was
translated from research to implementation as de-
identified frequency data in our clinical laboratory;
Sixthly) flexibility for integration with further clinical
research including additional diagnostic approaches,
knowledge management platforms, community engage-
ment, policy and models of care. This includes: i) whole
genome sequencing; ii) the planned implementation
of a knowledge management platforms for mining of
free text, case sharing, discussion and an application
programming interface to push data to Matchmaker
Exchange, namely Patient Archive; iii) community engage-
ment, such as that enabled through the delineation of acritical mass of diagnosed and undiagnosed patients and
relatedly by directly partnering with community peak
bodies to develop policy and models of care. Finally, less
tangible outcomes included: increased workplace satisfac-
tion for staff though improved access to molecular con-
firmation, as indicated by repetitive informal feedback,
and noting that this was not assessed through formal
surveys during the period described; and the potential
for professional development through the shared experi-
ences and quality improvements resulting from defini-
tive diagnoses.
The overall mutation detection rate was in accordance
with expectation at 30 %. Similar to other reports [8–10],
the diagnostic yield was proportional to the specificity of
the described phenotype, including affectation of multiple
organ systems, rather than a single organ system. This
was reflected in the following mutation detection rates
hereditary haemorrhagic telangiectasiae (5/5, 100 %),
RASopathies and overgrowth disorders (7/16, 44 %) and
presumed X-linked mental retardation (0/7, 0 %).
Two illustrative cases are described. Firstly, over a
10 year period an Aboriginal family from remote
Australia had been seen in an outreach clinic. Multiple
siblings had the same unique phenotype characterised
by intellectual disability, macrocephaly, small thoraces,
asymmetric visceral overgrowth, connective tissue
dysplasia, predisposition to infection, and variably one to
multiple cafe-au-lait lesions, hemi-megalencephaly with
perisylvian polymicrogyria. Over the decade, multiple
diagnoses had been considered and many monogenic
tests had been performed with normal results, largely to
investigate RASopathies and overgrowth disorders.
Guided by the phenotype, WES was targeted to genes
known to be associated with the two presumptive diag-
nostic groups and overlapping genes, including mTOR.
A likely pathogenic variant in mTOR was identified. The
mutation segregated with disease in the family. Follow-
ing a protracted search for a suitable laboratory, func-
tional studies were performed that supported a gain of
function mechanism for this gene [13]. This finding also
supported the possibility of mTOR inhibitor drug repur-
posing. This case highlights the importance of pheno-
typing; the need for coordinated access to functional
studies, such as in the first instance might be enabled by
a virtual network of functional analyses; and manage-
ment implications of a molecularly confirmed diagnosis.
In the second example, a child presented with features
consistent with megalencephaly-capillary malformation
syndrome; specifically, prenatal onset impressive macro-
cephaly, infantile onset hydrocephalus, capillary malfor-
mations and connective tissue dysplasia. Targeted exome
sequencing of PIK3CA and related genes was performed
on DNA extracted from peripheral blood and skin fibro-
blasts; a mosaic mutation was detected in the latter but
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Sanger sequencing of DNA from skin fibroblasts and
cerebrospinal fluid. This case again highlights the im-
portance of phenotyping to guide genomic analysis and
highlights the selection of an appropriate tissue for
testing.
Provision of this service within a public health setting
and with multi-expert review was an approach that was
tailored to local circumstances, including optimal use of
limited health resources targeted to the unmet need of a
population where it is was most likely to have immediate
clinical utility and deliver patient benefits. Key to the
patient-centric delivery of this service was the pivotal
involvement of genetic counsellors at multiple points in
the diagnostic pipeline and for ongoing support as
required. Other critical success factors included partner-
ships with translational research to augment future
diagnostic analytic capacity, promotion of access to
functional analysis, and the initiation of economic ana-
lyses and studies of patient and family experience, as
well as the development of improved models of care.
Similarly, active community engagement was informative
and supportive at all stages. Finally, the involvement of a
public health genomic policy unit supported implemen-
tation and sustainability.
By iterating within the clinical service, known or un-
anticipated real-world bottlenecks can be identified and
pragmatically addressed. Also, real-time in-service stud-
ies of health care provision can be performed and are in
progress. Process improvements to address identified
bottlenecks will need to include more timely ascertain-
ment of human phenotype ontology terms in a manner
aligned to clinical flow [14], as this will streamline com-
munications with the clinical laboratory and facilitate
the better use of phenotypic information in the analytic
workflow. Also, the need for capacity building including
promoting the development of a workforce that is
knowledgeable of the evolving relative place and limita-
tions of genomic and non-genomic investigations. Add-
itionally, given the significant proportion of cases that
remained undiagnosed, the need for complementary ap-
proaches for diagnostically intractable cases, including
local and international undiagnosed diseases programs
[15], was reinforced.
A limitation of this work which might also be viewed
as a critical success factor, was the lack of internal
consistency of some technical instrumentation and ana-
lytic tools used during the evaluation of this cohort. This
was reflective of and responsive to changes in technol-
ogy and was a testament to the endeavour and flexibility
of the laboratory team that delivered within the hetero-
geneity and imperfection of clinical process. What was
also demonstrated very clearly was that it was the
phenotype-informed and patient-centred processes thatwere instrumental to applying technology to enable
improved diagnostic yield.
Conclusion
We describe an iteratively improving diagnostic platform
provided within a public health service that is aligned
to the unmet needs of people living with rare and un-
diagnosed diseases, by supporting equitable state-wide
diagnostic health care provision for the world’s geograph-
ically largest public health jurisdiction. It is largely been
performed within existing budgets through a patient-
centric approach and clinically informed re-alignment of
existing resources.
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